First-line afatinib for the treatment of <i>EGFR</i> mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting.

Ther Adv Med Oncol · 2019 · PMC6466470 · PMID 31019567

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

34 A trend towards longer PFS with afatinib compared with erlotinib (HR 0.87 [95% CI 0.62–1.20]) did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.